Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs Topical Nicotinamide for Facial Actinic Keratosis
NCT07049068Phase 1Completed
- Sponsor
- Universidade Federal do Rio Grande do Sul
- Start
- Feb 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nicotinamide in actinic keratosis (AK) (2 arms), sponsored by Universidade Federal do Rio Grande do Sul. Primary endpoint: Facial Actinic Keratosis Count at 6 Months. Started Feb 2022; status: completed.
02
Drugs
nicotinamide
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT07049068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07049068.